Evidence map›Paper›PMID 21051857›Full record

ReviewCells, tissues, organs2011

The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.

Tressa M Allington, William P Schiemann

Open access · bronzeAbstract readReview
In one paragraph

Review in Cells, tissues, organs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. The role of cytokines in breast cancer development and progression.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2015
    Review
  8. The role of EphB4 and IGF-IR expression in breast cancer cells.International journal of clinical and experimental pathology · 2015
    Article
  9. Article
  10. A phosphotyrosine switch determines the antitumor activity of ERβ.The Journal of clinical investigation · 2014
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A roundabout way to cancer.Advances in cancer research · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution.

Tressa M AllingtonDepartment of Pharmacology, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colo., USA.
William P Schiemann
Case Comprehensive Cancer Center

Funding

Integrin-Mediated Regulation of TGF-Beta Signaling and TumorigenesisR01CA129359 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHIEMANN, WILLIAM · 2007 to 2016
$2.9M
Use of Cystatin C to Combat TGF-Beta TumorigenesisR01CA114039 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHIEMANN, WILLIAM · 2005 to 2009
$1.3M
NCI NIH HHS CA114039NCI NIH HHS CA129359NCI NIH HHS R01 CA114039NCI NIH HHS R01 CA129359
6 · The paper itself

Abstract

Transforming growth factor-β (TGF-β) normally inhibits breast cancer development by preventing mammary epithelial cell (MEC) proliferation, by inducing MEC apoptosis, and by creating cell microenvironments that maintain MEC homeostasis and prevent their uncontrolled growth and motility. Mammary tumorigenesis elicits dramatic alterations in MEC architecture and microenvironment integrity, which collectively counteract the tumor-suppressing activities of TGF-β and enable its stimulation of breast cancer invasion and metastasis. How malignant MECs overcome the cytostatic actions imposed by normal microenvironments and TGF-β, and how abnormal microenvironments conspire with TGF-β to stimulate the development and progression of mammary tumors remains largely undefined. These knowledge gaps have prevented science and medicine from implementing treatments effective in simultaneously targeting abnormal cellular microenvironments, and in antagonizing the oncogenic activities of TGF-β in developing and progressing breast cancers. c-Abl is a ubiquitously expressed nonreceptor protein tyrosine kinase that essentially oversees all aspects of cell physiology, including the regulation of cell proliferation, migration and adhesion, as well as that of cell survival. Thus, the biological functions of c-Abl are highly reminiscent of those attributed to TGF-β, including the ability to function as either a suppressor or promoter of tumorigenesis. Interestingly, while dysregulated Abl activity clearly promotes tumorigenesis in hematopoietic cells, an analogous role for c-Abl in regulating solid tumor development, including those of the breast, remains controversial. Here, we review the functions of c-Abl in regulating breast cancer development and progression, and in alleviating the oncogenic activities of TGF-β and its stimulation of epithelial-mesenchymal transition during mammary tumorigenesis.

Indexed as

AnimalsEpithelial CellsEpithelial-Mesenchymal TransitionFemaleHumansMammary Glands, AnimalMammary Glands, HumanTransforming Growth Factor betaTransforming Growth Factor beta

Identifiers

PMID21051857
PMCPMC3245834
OpenAlexW2069958696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.